Global Chemotherapy Induced Neutropenia(CIN)Drug Market Growth (Status and Outlook) 2025-2031
Description
The global Chemotherapy Induced Neutropenia（CIN）Drug market size is predicted to grow from US$ 615 million in 2025 to US$ 770 million in 2031; it is expected to grow at a CAGR of 3.8% from 2025 to 2031.
Chemotherapy-induced neutropenia (CIN) drugs refer to drugs used to prevent or treat chemotherapy-induced neutropenia. These drugs are mainly recombinant Human granulocyte colony-stimulating factor (rhG-CSF) and its pegylated form, which increase the number of neutrophils in the blood by stimulating the production of neutrophils in the bone marrow, thereby reducing the risk of infection in patients. These drugs play an important role in the supportive treatment of chemotherapy patients.
United States market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Chemotherapy Induced Neutropenia（CIN）Drug players cover Sandoz, Apotex, Pfizer, Teva Pharmaceuticals, Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Chemotherapy Induced Neutropenia（CIN）Drug Industry Forecast” looks at past sales and reviews total world Chemotherapy Induced Neutropenia（CIN）Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Chemotherapy Induced Neutropenia（CIN）Drug sales for 2025 through 2031. With Chemotherapy Induced Neutropenia（CIN）Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chemotherapy Induced Neutropenia（CIN）Drug industry.
This Insight Report provides a comprehensive analysis of the global Chemotherapy Induced Neutropenia（CIN）Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chemotherapy Induced Neutropenia（CIN）Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chemotherapy Induced Neutropenia（CIN）Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chemotherapy Induced Neutropenia（CIN）Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chemotherapy Induced Neutropenia（CIN）Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Neutropenia（CIN）Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Injection
Oral Preparation
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sandoz
Apotex
Pfizer
Teva Pharmaceuticals
Amgen
Assertio Holdings
B. Braun Holding GmbH
CSPC Pharmaceutical Group
Qilu Pharmaceutical
Shandong New Era Pharmaceutical
Chongqing Fujin Biological Medicine
Jiuyuan Gene
Evive Biopharma
Yifan Pharmaceutical
Xiamen Amoytop Biotech
Beijing SL Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Chemotherapy-induced neutropenia (CIN) drugs refer to drugs used to prevent or treat chemotherapy-induced neutropenia. These drugs are mainly recombinant Human granulocyte colony-stimulating factor (rhG-CSF) and its pegylated form, which increase the number of neutrophils in the blood by stimulating the production of neutrophils in the bone marrow, thereby reducing the risk of infection in patients. These drugs play an important role in the supportive treatment of chemotherapy patients.
United States market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Chemotherapy Induced Neutropenia（CIN）Drug players cover Sandoz, Apotex, Pfizer, Teva Pharmaceuticals, Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Chemotherapy Induced Neutropenia（CIN）Drug Industry Forecast” looks at past sales and reviews total world Chemotherapy Induced Neutropenia（CIN）Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Chemotherapy Induced Neutropenia（CIN）Drug sales for 2025 through 2031. With Chemotherapy Induced Neutropenia（CIN）Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chemotherapy Induced Neutropenia（CIN）Drug industry.
This Insight Report provides a comprehensive analysis of the global Chemotherapy Induced Neutropenia（CIN）Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chemotherapy Induced Neutropenia（CIN）Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chemotherapy Induced Neutropenia（CIN）Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chemotherapy Induced Neutropenia（CIN）Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chemotherapy Induced Neutropenia（CIN）Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Neutropenia（CIN）Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Injection
Oral Preparation
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sandoz
Apotex
Pfizer
Teva Pharmaceuticals
Amgen
Assertio Holdings
B. Braun Holding GmbH
CSPC Pharmaceutical Group
Qilu Pharmaceutical
Shandong New Era Pharmaceutical
Chongqing Fujin Biological Medicine
Jiuyuan Gene
Evive Biopharma
Yifan Pharmaceutical
Xiamen Amoytop Biotech
Beijing SL Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
139 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Player
- 4 Chemotherapy Induced Neutropenia（CIN）Drug by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Chemotherapy Induced Neutropenia（CIN）Drug Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
